摘要:

Background: Due to the increasingly common use of endocrine therapy in adjuvant and palliative therapy of breast cancer, a significant number of patients will be treated with radiation therapy and Tamoxifen (TMX) at the same time. Methods: MCF-7 breast cancer cells, cultured by standard methods, were treated with varying doses of TMX or estrogen (ES) and/or graded doses of X-rays. The effects were measured by a clono-genic survival assay. Results: We found a marked decrease in the radiosensitivity of MCF-7 cells which were treated with TMX. This effect was time- and concentration-dependent, with a maximum at a 72-hour incubation. Treatment of the cells with estrogen (ES) increased their radiosensitivity at very high ES doses only. Conclusion: For patients treated with radiotherapy and TMX simultaneously, a negative effect can not be excluded.

ISSN:0378-584X    

DOI:10.1159/000218846

出版商:S. Karger GmbH    

年代:1996

数据来源: Karger

摘要:

Background: Pentostatin (Nipent®), a potent inhibitor of adenosine deaminase, has proven its efficacy in the treatment of hairy-cell leukemia. However, there are only few reports on the pentostatin treatment of prolymphocytic leukemia (PLL), a disease with generally poor response to conventional chemotherapy consisting of anthracycline-containing combinations. Case Report: We report on a 64-year-old female patient in whom PLL was diagnosed in September 1995. The leukemic bone marrow infiltration at diagnosis was 90%. The initial hy-perleukocytosis of 850,000/μlwas reduced by leukapheresis to 600,000 leukocytes/μl. Chemotherapy with Vincristine, Adria-mycin and cortisone reduced the leukocytes to 150,000/μl; a second course of the same chemotherapy did not further decrease the leukocyte counts. In contrast, 3 doses of pentostatin induced a partial remission within 4 weeks with normal peripheral blood cell counts and with a leukemic bone marrow infiltration of only 25%. Pentostatin was tolerated without any side effects. In spite of continued pentostatin administration for 2 months, the patient relapsed and died from tumor progress. Conclusions: Pentostatin may be efficacious in the treatment of PLL, even in conventionally pretreated patients. Pentostatin treatment alone, however, may not be sufficient to significantly alter the natural course of the PLL, but requires additional therapeutic age

ISSN:0378-584X    

DOI:10.1159/000218847

出版商:S. Karger GmbH    

年代:1996

数据来源: Karger

摘要:

Background: Communications concerning Hodgkin’s disease (HD) after non-Hodgkin’s lymphoma (NHL) are rather rare, whereas NHL after HD represents a common form of dual lymphoma. Patient: A 68-year-old woman developed nodular sclerosing HD of the upper mediastinum and right supracla-vicular fossa stage ΠB 2 years after splenectomy for a splenic lymphoplasmocytoid immunocytoma. She died of septic infection after 2 cycles of COPP-ABVD and a thoracic mantle field radiation during extended field radiation of paraaortic lymph nodes. Conclusion: If new lymph node enlargements occur during long-time management of patients with malignant lymphoma, repeated histologie investigations are imperative in order to separate between relapse, transformation or a dual lymphoma. Concordant with current literature we assume that patients with NHL are at an increased risk to have HD. They are almost twice as old as patients with primary HD, mostly have a nodular sclerosing histology and a poor prognosis. The development of HD as a secondary lymphoma is mainly due to unbalanced immune competence and not to precedent cytotoxic the

ISSN:0378-584X    

DOI:10.1159/000218848

出版商:S. Karger GmbH    

年代:1996

数据来源: Karger

摘要:

Background: Granulocyte colony-stimulating factor (G-CSF) is widely used to treat chemo- or radiotherapy-induced neutro-penia and is also effective in the treatment of severe oral mu-cositis induced by chemotherapy. With the common use of G-CSF the description of rare or new side effects becomes more important. Case Report: The 44-year-old male patient suffered from an inoperable carcinoma of the nasopharynx and underwent a combined radio-chemotherapy, consisting of paclitaxel weekly and irradiation with 70 Gy over 7 weeks. During the course of treatment, he developed a severe oral mucositis. Since conventional therapy of mucositis did not alleviate the symptoms, he was treated with G-CSF. Within 18 h after the subcutaneous administration of G-CSF he developed a severe facial angioedema. Within 3 days the patient recovered spontaneously from the angioedema. Because the relationship of the symptoms and the G-CSF treatment was not clearly evident, a second dose of G-CSF was given. 14 h after the subcutaneous injection of the same dose of G-CSF, the patient developed the identical symptoms of angioedema. Conclusion: Facial angioedema is a rare but important side effect after G-CSF treatment. A possible role of paclitaxel or radiation therapy in the pathogenesis of this side effect cannot be ruled out.

ISSN:0378-584X    

DOI:10.1159/000218849

出版商:S. Karger GmbH    

年代:1996

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000218850

出版商:S. Karger GmbH    

年代:1996

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000218851

出版商:S. Karger GmbH    

年代:1996

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000218852

出版商:S. Karger GmbH    

年代:1996

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000218853

出版商:S. Karger GmbH    

年代:1996

数据来源: Karger